Sunshine Guojian Pharmaceutical(688336.SH)

Last Updated 00:00:00
longbridge loading

Innovative drug concept stocks rapidly plummeted, with NEPTUNUS hitting the daily limit, RemeGen falling more than 10%, and many stocks including Cosunter, Rundu Pharma, Sunshine Guojian Pharmaceutical, SL PHARM, and HITECK dropping more than 6%

Wallstreetcn·
SH
512290
-0.85%
SZ
002038
-2.07%
SZ
002923
-2.85%
Wallstreetcn·
SH
512290
-0.85%
SZ
002038
-2.07%
SZ
002923
-2.85%

Pharmaceutical stocks fluctuated and surged, with Getein Biotech hitting the daily limit, RemeGen rising nearly 7%, reaching a historical high. Sunshine Guojian Pharmaceutical, EASTON BIOPHARMACEUTICALS, YKYY, Junshi Biosciences, BeBetter Med, and InventisBio also followed suit

Wallstreetcn·
SH
688336
-2.61%
SH
688513
-2.11%
HK
01877
+0.27%
Wallstreetcn·
SH
688336
-2.61%
SH
688513
-2.11%
HK
01877
+0.27%

Sunshine Guojian Pharmaceutical: Pfizer has registered two global Phase III clinical trials for the PD-1/VEGF dual antibody PF-08634404 (SSGJ-707) on a certain website, and the final payment remains uncertain

Zhitong·
SH
688336
-2.61%
Zhitong·
SH
688336
-2.61%

A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suit

Zhitong·
SZ
300878
-0.24%
SZ
300497
-0.49%
SZ
002940
-8.91%
Zhitong·
SZ
300878
-0.24%
SZ
300497
-0.49%
SZ
002940
-8.91%

Midday Review: The Beijing Stock Exchange 50 Index surged over 3% in the first half of the day, with strong performance in AI application sectors such as film and media

Zhitong·
SH
688336
-2.61%
SZ
300071
-4.68%
SH
601360
-2.23%
Zhitong·
SH
688336
-2.61%
SZ
300071
-4.68%
SH
601360
-2.23%

Sunshine Guojian Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 399 million yuan, a year-on-year increase of 71.15%

Zhitong·
SH
688336
-2.61%
Zhitong·
SH
688336
-2.61%

Sunshine Guojian Pharmaceutical: Net profit of 190 million yuan in the first half of 2025, a year-on-year increase of 46.96%

Zhitong·
SH
688336
-2.61%
Zhitong·
SH
688336
-2.61%

The concept of innovative drugs is active again, Shen Lian Biomedical has achieved a two-day limit up

Zhitong·
SH
688336
-2.61%
SH
688098
-2.46%
SZ
300049
+0.79%
Zhitong·
SH
688336
-2.61%
SH
688098
-2.46%
SZ
300049
+0.79%

Sunshine Guojian Pharmaceutical: Projects 608 and 613 have both submitted new drug marketing applications to the CDE and have been accepted

Zhitong·
SH
688336
-2.61%
Zhitong·
SH
688336
-2.61%
© 2026 Longbridge｜Disclaimer